Neurosense Therapeutics Stock Net Income
| NRSN Stock | USD 0.88 0.08 8.28% |
As of the 27th of January, Neurosense Therapeutics secures the Risk Adjusted Performance of (0.02), mean deviation of 4.49, and Standard Deviation of 6.13. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Neurosense Therapeutics, as well as the relationship between them.
Neurosense Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Neurosense Therapeutics' valuation are provided below:We have found one hundred twenty available fundamental ratios for Neurosense Therapeutics, which can be analyzed and compared to other ratios and to its peers in the industry. Self-guided Investors are advised to check Neurosense Therapeutics' last-minute fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -9.2 M | -9.6 M | |
| Net Loss | -3.6 M | -3.8 M | |
| Net Loss | -9.2 M | -9.6 M | |
| Net Loss | (0.63) | (0.66) | |
| Net Income Per E B T | 0.90 | 0.80 |
Neurosense | Net Income | Build AI portfolio with Neurosense Stock |
Latest Neurosense Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Neurosense Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Neurosense Therapeutics financial statement analysis. It represents the amount of money remaining after all of Neurosense Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Neurosense Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Neurosense Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (10.21 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Neurosense Net Income Regression Statistics
| Arithmetic Mean | (4,154,909) | |
| Coefficient Of Variation | (101.06) | |
| Mean Deviation | 3,614,107 | |
| Median | (1,227,000) | |
| Standard Deviation | 4,199,021 | |
| Sample Variance | 17.6T | |
| Range | 11.1M | |
| R-Value | (0.82) | |
| Mean Square Error | 6.2T | |
| R-Squared | 0.67 | |
| Significance | 0.00006 | |
| Slope | (680,146) | |
| Total Sum of Squares | 282.1T |
Neurosense Net Income History
Other Fundumenentals of Neurosense Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Neurosense Therapeutics Net Income component correlations
Neurosense Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Neurosense Therapeutics is extremely important. It helps to project a fair market value of Neurosense Stock properly, considering its historical fundamentals such as Net Income. Since Neurosense Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Neurosense Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Neurosense Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurosense Therapeutics. If investors know Neurosense will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurosense Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Neurosense Therapeutics is measured differently than its book value, which is the value of Neurosense that is recorded on the company's balance sheet. Investors also form their own opinion of Neurosense Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Neurosense Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurosense Therapeutics' market value can be influenced by many factors that don't directly affect Neurosense Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurosense Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurosense Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurosense Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Neurosense Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Neurosense Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Neurosense Therapeutics.
| 10/29/2025 |
| 01/27/2026 |
If you would invest 0.00 in Neurosense Therapeutics on October 29, 2025 and sell it all today you would earn a total of 0.00 from holding Neurosense Therapeutics or generate 0.0% return on investment in Neurosense Therapeutics over 90 days. Neurosense Therapeutics is related to or competes with Neuraxis, Klotho Neurosciences, Collplant Biotechnologies, Exicure, Cadrenal Therapeutics, Enlivex Therapeutics, and Minerva Neurosciences. NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments f... More
Neurosense Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Neurosense Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Neurosense Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.05) | |||
| Maximum Drawdown | 34.62 | |||
| Value At Risk | (7.48) | |||
| Potential Upside | 12.82 |
Neurosense Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Neurosense Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Neurosense Therapeutics' standard deviation. In reality, there are many statistical measures that can use Neurosense Therapeutics historical prices to predict the future Neurosense Therapeutics' volatility.| Risk Adjusted Performance | (0.02) | |||
| Jensen Alpha | (0.29) | |||
| Total Risk Alpha | (0.82) | |||
| Treynor Ratio | (0.25) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Neurosense Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Neurosense Therapeutics January 27, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.24) | |||
| Mean Deviation | 4.49 | |||
| Coefficient Of Variation | (2,804) | |||
| Standard Deviation | 6.13 | |||
| Variance | 37.57 | |||
| Information Ratio | (0.05) | |||
| Jensen Alpha | (0.29) | |||
| Total Risk Alpha | (0.82) | |||
| Treynor Ratio | (0.25) | |||
| Maximum Drawdown | 34.62 | |||
| Value At Risk | (7.48) | |||
| Potential Upside | 12.82 | |||
| Skewness | 0.8282 | |||
| Kurtosis | 1.49 |
Neurosense Therapeutics Backtested Returns
Neurosense Therapeutics has Sharpe Ratio of close to zero, which conveys that the firm had a close to zero % return per unit of risk over the last 3 months. Neurosense Therapeutics exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please verify Neurosense Therapeutics' Mean Deviation of 4.49, risk adjusted performance of (0.02), and Standard Deviation of 6.13 to check out the risk estimate we provide. The company secures a Beta (Market Risk) of 0.91, which conveys possible diversification benefits within a given portfolio. Neurosense Therapeutics returns are very sensitive to returns on the market. As the market goes up or down, Neurosense Therapeutics is expected to follow. At this point, Neurosense Therapeutics has a negative expected return of -0.0334%. Please make sure to verify Neurosense Therapeutics' value at risk, daily balance of power, as well as the relationship between the Daily Balance Of Power and price action indicator , to decide if Neurosense Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.59 |
Modest predictability
Neurosense Therapeutics has modest predictability. Overlapping area represents the amount of predictability between Neurosense Therapeutics time series from 29th of October 2025 to 13th of December 2025 and 13th of December 2025 to 27th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Neurosense Therapeutics price movement. The serial correlation of 0.59 indicates that roughly 59.0% of current Neurosense Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.59 | |
| Spearman Rank Test | 0.3 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Neurosense Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Neurosense Therapeutics reported net income of (10.21 Million). This is 102.99% lower than that of the Biotechnology sector and 114.58% lower than that of the Health Care industry. The net income for all United States stocks is 101.79% higher than that of the company.
Neurosense Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Neurosense Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Neurosense Therapeutics could also be used in its relative valuation, which is a method of valuing Neurosense Therapeutics by comparing valuation metrics of similar companies.Neurosense Therapeutics is currently under evaluation in net income category among its peers.
Neurosense Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Neurosense Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Neurosense Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Neurosense Therapeutics' value.| Shares | Cwm, Llc Duplicate | 2025-06-30 | 1000 | Total Investment Management Inc | 2025-06-30 | 500 | Warberg Asset Management Llc | 2025-06-30 | 0.0 | Stratos Wealth Partners, Ltd | 2025-03-31 | 0.0 | Xtx Topco Ltd | 2025-06-30 | 0.0 | Two Sigma Securities, Llc | 2025-06-30 | 0.0 | Citadel Advisors Llc | 2025-06-30 | 149.2 K | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 79.9 K | Squarepoint Ops Llc | 2025-06-30 | 49.9 K | Meitav Dash Investments Ltd | 2025-06-30 | 40 K | Jane Street Group Llc | 2025-06-30 | 28.7 K |
Neurosense Fundamentals
| Return On Equity | -24.78 | ||||
| Return On Asset | -3.04 | ||||
| Current Valuation | 25.18 M | ||||
| Shares Outstanding | 29.55 M | ||||
| Shares Owned By Insiders | 25.55 % | ||||
| Shares Owned By Institutions | 1.71 % | ||||
| Number Of Shares Shorted | 555.31 K | ||||
| Price To Book | 12.82 X | ||||
| EBITDA | (9.88 M) | ||||
| Net Income | (10.21 M) | ||||
| Cash And Equivalents | 10.37 M | ||||
| Cash Per Share | 0.89 X | ||||
| Total Debt | 73 K | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 15.09 X | ||||
| Book Value Per Share | (0.02) X | ||||
| Cash Flow From Operations | (10.13 M) | ||||
| Short Ratio | 1.15 X | ||||
| Earnings Per Share | (0.36) X | ||||
| Target Price | 11.5 | ||||
| Number Of Employees | 17 | ||||
| Beta | 1.57 | ||||
| Market Capitalization | 27.11 M | ||||
| Total Asset | 4.58 M | ||||
| Retained Earnings | (36.66 M) | ||||
| Working Capital | 2.41 M | ||||
| Net Asset | 4.58 M |
About Neurosense Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Neurosense Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neurosense Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neurosense Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Neurosense Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Neurosense Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Neurosense Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Neurosense Stock
Moving against Neurosense Stock
| 0.66 | LYEL | Lyell Immunopharma | PairCorr |
| 0.62 | HLN | Haleon plc Aggressive Push | PairCorr |
| 0.58 | CAPR | Capricor Therapeutics | PairCorr |
| 0.57 | DBVT | DBV Technologies | PairCorr |
| 0.57 | CNOB | ConnectOne Bancorp Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Neurosense Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Neurosense Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Neurosense Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Neurosense Therapeutics to buy it.
The correlation of Neurosense Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Neurosense Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Neurosense Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Neurosense Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Neurosense Therapeutics Piotroski F Score and Neurosense Therapeutics Altman Z Score analysis. To learn how to invest in Neurosense Stock, please use our How to Invest in Neurosense Therapeutics guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurosense Therapeutics. If investors know Neurosense will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurosense Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Neurosense Therapeutics is measured differently than its book value, which is the value of Neurosense that is recorded on the company's balance sheet. Investors also form their own opinion of Neurosense Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Neurosense Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurosense Therapeutics' market value can be influenced by many factors that don't directly affect Neurosense Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurosense Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurosense Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurosense Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.